KEY POINTS:
Three wound dressing products developed by Wool Equities have been given the green light by the European Union for use as medical devices.
The dressings - approved through the CE marking process - were developed through Wool Equities subsidiary Keratec in collaboration with US-based Keraplast for use on chronic wounds.
Keratec chief executive Elizabeth Hopkins said they were the first keratin-containing medical devices to be given approval by any global regulatory body.
"Gaining the CE mark greatly enhances the value proposition for potential partner companies and significantly de-risks the biomedical area of our business."
